Sangamo Therapeutics announced the publication in Nature Communications of improvements to its zinc finger nuclease, or ZFN, platform technology, which yield a 64-fold increase in the diversity of ZFNs available for targeting any DNA segment. As demonstrated in the manuscript, this improved targeting capability enables highly precise editing of chosen genomic loci. ZFN technology is an engineerable gene editing platform that is currently being evaluated in clinical trials for Mucopolysaccharidosis Type I, MPS II, hemophilia B, beta thalassemia and sickle cell disease. The manuscript, “Diversifying the Structure of Zinc Finger Nucleases for High-Precision Genome Editing,” describes protein engineering work by Dr. David Paschon and colleagues at Sangamo that has led to the development of new ZFN architectures. The modifications include the reversal of the order of the DNA binding and nuclease domains, as well as the incorporation of new linkers that enable base skipping between otherwise adjacent fingers within each ZFN.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.